ATOS - Atossa Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
0
0
0
0
Cost of Revenue
-
-
-
0
Gross Profit
-
-
-
0
Operating Expenses
Research Development
6,597
4,210
2,328
770
Selling General and Administrative
10,159
7,224
4,859
6,479
Total Operating Expenses
16,756
11,434
7,187
7,250
Operating Income or Loss
-16,756
-11,434
-7,187
-7,250
Interest Expense
-
-
193
-
Total Other Income/Expenses Net
56
29
-935
881
Income Before Tax
-16,700
-11,405
-8,123
-6,369
Income Tax Expense
-
-
-
0
Income from Continuing Operations
-16,700
-11,405
-8,123
-6,369
Net Income
-16,700
-11,405
-8,123
-6,369
Net Income available to common shareholders
-16,700
-22,884
-10,691
-6,369
Reported EPS
Basic
-
-5.50
-10.92
-33.60
Diluted
-
-5.50
-10.92
-33.60
Weighted average shares outstanding
Basic
-
4,158
975
190
Diluted
-
4,158
975
190
EBITDA
-
-11,390
-7,187
-6,946